Characterization of a hospital-based gastroenteritis outbreak caused by GII.6 norovirus in Jinshan, China

X. F. Zhang1,*, J. R. Chen1,*, C. L. Song2,*, D. J. Xie1,*, M. Tan3,4, L. Wang5, M. M. Koroma5, Y. Z. Hou5, Z. P. Dong2, J. R. Yu5, W. T. Duan1, D. D. Zhao1, J. R. Du2, L. Zhu2 and Y. C. Dai5

1School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China; 2Jinshan District Center for Disease Control and Prevention, Shanghai 201599, China; 3Divisions of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Ohio, USA; 4Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA and 5Department of Epidemiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China

Abstract
An acute gastroenteritis (AGE) outbreak caused by a norovirus occurred at a hospital in Shanghai, China, was studied for molecular epidemiology, host susceptibility and serological roles. Rectal and environmental swabs, paired serum samples and saliva specimens were collected. Pathogens were detected by real-time polymerase chain reaction and DNA sequencing. Histo-blood group antigens (HBGA) phenotypes of saliva samples and their binding to norovirus protruding proteins were determined by enzyme-linked immunosorbent assay. The HBGA-binding interfaces and the surrounding region were analysed by the MegAlign program of DNastar 7.1. Twenty-seven individuals in two care units were attacked with AGE at attack rates of 9.02 and 11.68%. Eighteen (78.2%) symptomatic and five (38.4%) asymptomatic individuals were GII.6/b norovirus positive. Saliva-based HBGA phenotyping showed that all symptomatic and asymptomatic cases belonged to A, B, AB or O secretors. Only four (16.7%) out of the 24 tested serum samples showed low blockade activity against HBGA-norovirus binding at the acute phase, whereas 11 (45.8%) samples at the convalescence stage showed seroconversion of such blockade. Specific blockade antibody in the population played an essential role in this norovirus epidemic. A wide HBGA-binding spectrum of GII.6 supports a need for continuous health attention and surveillance in different settings.

Introduction
Noroviruses are the leading causative agent of acute gastroenteritis (AGE), infecting peoples of all age groups. These viruses are responsible for about a fifth (18%) of all AGE cases worldwide, leading to about 685 million illnesses, 210 000 deaths and 15 million disability-adjusted life years annually [1]. In recent years, many countries have been experiencing an increase in AGE outbreaks associated with noroviruses, causing significant disease burden [2, 3]. Currently, there is no vaccine or specific treatment against noroviruses.

Noroviruses are single-stranded, positive-sense RNA viruses with a genome of 7.5–7.7 kb, being divided into 10 genogroups (GI–GX) [4]. Noroviruses use glycans of histo-blood group antigen (HBGA) for attachment to their target cells. These glycans are mainly controlled by the fucosyltransferase 2 (FUT2) in secretors, FUT3 (Lewis) and the ABH genes families. Individuals with FUT2 enzyme expressions are secretor-positive, while those without are secretor-negative and they do not express ABH HBGAs on mucosal surfaces [5–7]. Various HBGAs binding profiles of norovirus-HBGA interactions are typical among different norovirus genotypes. The GII.6 noroviruses are consistently associated with infections among young children and the elderly [8, 9]. Genogroups II.6 were the second most common genogroup in active AGE surveillance from 2011 to 2015 in the USA [10]. Studies revealed it tended to infect FUT2 secretor status [11] and was significantly less likely to have symptoms in non-secretors [12]. Another study analysing sequential outbreaks caused by GII.2 and GII.6 noroviruses in institutional settings revealed that 21% of residents who shed GII.6 noroviruses and developed antibodies against GII.6, were secretor-negative [13]. Genogroups II.6 noroviruses consist of three clusters, differing in amino acid residues (5.2–9.2%) from each other that can be detected after 40 years [14]. Herd immunity to noroviruses is complicated due to its diversity. Thus, the roles of HBGA and immunity statuses of individuals on GII.6 norovirus infections require further investigations.
Here, we reported an AGE outbreak caused by GII.6/b noroviruses in November 2018 at a hospital in Jinshan District, Shanghai, China. Studies on molecular epidemiology, host susceptibility and serological roles were performed to understand the GII.6/b noroviruses as an AGE outbreak agent.

Materials and methods

Outbreak investigation and samples collection

An AGE outbreak occurred from 23 to 29 November 2018 at a specialised hospital in Jinshan District, Shanghai, China. Symptomatic cases were defined as individuals who experienced symptoms of at least one episode of vomiting and diarrhoea from 23 November. Confirmed cases were those whose stool specimen or rectal swab was positive for norovirus. Asymptomatic cases were defined as those who did not experience symptoms of vomiting or diarrhoea but whose stool specimen or rectal swab was positive for norovirus [15].

The affected hospital contained four care units (CU) with 439 inpatients and 111 staff, including 24 doctors, 75 nurses, seven canteen food workers and five logistic workers. The four CU were on different floors. Each of the CU had 12 wards, one public toilet, a public bathroom and a common activity room for all inpatients. The wards were in proximity but without a bathroom.

Twenty-three stool samples were collected from symptomatic individuals (22 inpatients and one doctor). Additionally, 13 stool samples from asymptomatic individuals were collected from a patient who shared the ward with the index case, seven canteen food workers and five from logistic workers. Continuous collections and norovirus detection of stool samples were performed for those staff with positive results on 3, 7, 10, 17 and 24 December. Out of 25 saliva samples, 20 from symptomatic and five asymptomatic individuals were collected. Twenty-two paired serum samples from symptomatic individuals at the acute phase (within 1 week after onset date) and convalescent phase (about 4 weeks after the onset date). Furthermore, two paired serum samples from asymptomatic individuals at the parallel time were also collected.

Pathogens detection, cloning and sequencing of the norovirus P domain

Norovirus was detected using a one-step real-time polymerase chain reaction (PCR) with GI and GII primers [16] and primer COG2F and GII8KR targeting at NS terminus of ORF 2 were further used for further genotyping [17]. Positive PCR products were sequenced and norovirus genotype was determined by genotyping tool [18].

The P domain of the outbreak norovirus strain (Jinshan 06) was amplified using primers GII.6-F: 5′-CGGATCCCTCA AAGACTAACCGCTTATCA-3′ and GII.6-R: 5′-GATGCGGC GCCAATGAAAAAGCATGACCGCAATGCGATT-3′. The reverse primer was linked by a cysteine-containing peptide (P-CDRCGDCFC) to C-terminus, as described previously [19]. The P domain sequences were cloned into T-vectors (Thermo Fisher, US). Phylogenetic trees were constructed using the neighbour-joining method (MEGA 6.0).

HBGA phenotyping of saliva samples

HBGA phenotyping of saliva samples was performed as described earlier [20]. Boiled saliva at a dilution of 1:1000 was coated on 96-well ELISA plates (high binding, Costar, Corning, CN). After blocking with PBS – 5% non-fat milk, monoclonal antibodies (anti – A, B and H, Santa Cruz, CA, USA; Lea, Leb, Lex and Ley, Signet Laboratories Inc., Dedham, MA, USA) at a dilution of 1:300 were added to detect HBGAs. The signals were read using a TMB substrate kit. The cut-off of a positive signal was set at 0.2 as an approximate value of the mean of the background/blank wells adding a triple standard deviation. As quality controls, well-characterised positive and negative saliva samples were added in each plate.

HBGA binding profiles of GII.6 norovirus

Saliva-based HBGA-P protein-binding assay was performed as described in Ref. [21]. Well-characterised boiled saliva samples [22] at 1:1000 dilution were coated onto plates overnight at 4 °C. After blocking with 5% PBS-non-fat milk, P proteins at a concentration of 5μg/ml of the outbreak strain were added and incubated at 37 °C for 1 h. Then our in-house made mice anti-GII.6 norovirus (dilution, 1:3000) sera were added, followed with HRP-conjugated goat anti-mouse IgG at 1:5000. The cut-off of a positive signal was set at 0.2.

GII.6 norovirus specific IgG antibody titres in paired sera

Plates were coated with 0.5μg/ml diluted P protein of the outbreak strain. After blocking with 5% non-fat milk in PBS, patient serum samples at serial twofold dilution (1:500–1:128 000) were added. The bound norovirus antibodies were then detected by horseradish peroxidase (HRP)-conjugated goat anti-human IgG (dilution, 1:3000). A cut-off was also set at OD50 = 0.2 and a titre of <500 was assigned to a value of 250. Seroconversion was defined as ≥fourfold increase in titre of the convalescent-phase serum sample compared with that of the acute-phase serum sample.

Blockade of the binding of P protein to HBGAs in saliva by paired sera

A well-characterised saliva sample with HBGA phenotypes of B, Leb and Le2, which showed good stable binding to the P protein of GII.6 norovirus, was used in HBGA blockade assays. The blockade assay was HBGA binding assay (see above) with an extra blockade step. The P proteins (5μg/ml) of GII.6 norovirus were pre-incubated with paired sera in twofold serial dilution (1:25–1:3200) for 1 h at 37 °C and added to the coated saliva. The positive control consisted of P proteins without pre-incubation with a serum sample and showed ODs of 1.0 ± 0.3 [23]. The 50% blocking titre (BT50) defined as the maximal dilutions (folds) of a serum sample that showed at least 50% blockade in OD compared with the positive control. Serum samples with a BT50 <25 were assigned a value of 12.5 [23].

Statistical analysis

The correlation between IgG and serum blockade titres was determined using the Pearson correlation coefficient test by SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).
Results

Descriptive epidemiology

A total of 27 AGE cases (26 inpatients and one doctor) in two care units met case criteria. All cases were males with a median age of 45.1, ranging from 27 to 65 years. The main symptoms included vomiting (77.1%) and diarrhoea (44.4%) (Table 1).

The index case was a 60-year-old male in CU4 with sudden onset symptoms of diarrhoea at 4:00 a.m. on 23 November. He experienced four episodes of watery diarrhoea and four episodes of vomiting in the public toilet room of CU4. Eleven cases were later identified in the same unit, with an attack rate of 9.02% (11/122) from 23 to 25 November. The first case in CU3 was a 30-year-old male on 26 November and had two episodes of watery diarrhoea and one episode of vomiting from 9:30 p.m to 11:00 p.m in the public toilet room of CU3. Sixteen cases were later identified in CU3 with an attack rate of 11.68% (16/137) between 26 and 29 November (Fig. 1).

Since this was a particular hospital for mental health patients, movement, food and drinking water were strictly regulated, excluding pathogens from other resources out of the hospital. Drinking water was supplied in the whole hospital. The fact that only CU4 and CU3 patients were infected indicated that water-borne was unlikely the cause of the outbreak.

Norovirus detection and phylogenetic analysis

Eighteen (78.26%, 17 inpatients and one doctor) out of 23 symptomatic cases and five (38.46%, two food workers, two logistic workers and one inpatient) out of 13 asymptomatic individuals were positive with GII.6 norovirus. The 23 sequences showed 99.7–100% nucleotide identity, indicating that this was a GII.6 norovirus outbreak (Fig. 2a). Further analysis of the P domain sequence revealed that the outbreak strain belonged to the GII.6/b cluster, sharing 99.3% homology with Groningen strain (LN854568) in the Netherlands (Fig. 2b). One confirmed symptomatic case and five (three males and two females) asymptomatic cases were found among the staff, including one doctor, two food workers and two logistic workers. No previous gastrointestinal illness was reported from all asymptomatic cases. Notably, two food handlers, who were positive for GII.6 norovirus without symptoms, were highly suspected as the source of the outbreak.

Among the confirmed cases, the doctor had diarrhoea at 2:00 a.m. on 28 November. He was in charge of CU3 and took on night shifts in CU4 and, thus, could have been the virus carrier leading to the second wave of outbreak. A high norovirus positive rate at 33.3% (4/12) from asymptomatic food and logistic workers was observed, who had high opportunities to spread the viruses. Furthermore, we noted that two infected staff (the doctor and one logistic worker) shed viruses for at least 19 days (until 17 December). This viral shedding might have contributed to spreading further and played a role in norovirus transmission.

HBGA-binding interfaces and the surrounding regions of GII.6 clusters

Although the sequence alignment by using MegAlign program of DNAstar 7.1 of different GII.6 clusters revealed highly conserved amino acids in HBGA-binding interfaces and the surrounding regions (Fig. 3), some variations were still observed. Compared with cluster a, one residue deletion in region 1 (A/–345) was seen in the HBGA-binding interfaces in clusters b and c, and a D–N mutation in the surrounding regions was also found in clusters b and c. Besides, one N/D/T/G390 mutation was also observed in region 2 among different clusters.

HBGA phenotyping of saliva samples

The HBGA phenotypes of the saliva samples from 20 symptomatic and five asymptomatic infections were determined. Secretors were characterised by antigen content: H and A antigens for phenotype A; H, A and B antigens for the AB phenotype; H and B antigens for phenotype B; and H antigen for phenotype O. The phenotype of the non-secretors was characterised by low secretion of ABH antigens in saliva [26]. All of them were identified as secretors, including seven A, nine B, two AB and seven O blood types (Table 1).

HBGA binding spectrum of the epidemic GII.6 variant

The results showed GII.6 P proteins bound saliva of type A, B, AB and O secretors. The binding signals were highest for type B and moderate for type A, AB and O saliva samples. However, there were no positive signals to the saliva of non-secretors (Fig. 4). The results were consistent with the observed HBGA-related host susceptibility.

Serum IgG titres of outbreak patients and blockade titres specific to GII.6 norovirus

The paired serum samples from both acute and convalescent phases were analysed for their GII.6 norovirus-specific IgG titres. Out of the 24 acute phase sera of cases, 20 (83.3%) possessed relatively high IgG titres of between 1000 and 8000. The IgG of the symptomatic cases showed higher titres in convalescent-phase sera, among which 19 showed ≥fourfolds increase (Fig. 5a). Two paired serum samples of asymptomatic cases did not show seroconversion.

With regards to blockade titres, only four out of the 24 individuals in the acute phase showed low detectable BT₅₀ at 25 or 50. Among the symptomatic cases, 11 (11/22, 50%) sera revealed ≥fourfolds blockade titre increase against GII.6 norovirus (Fig. 5b). Two paired serum samples of asymptomatic cases did not reveal a blockade seroconversion. These results indicated diverse immune responses to the GII.6 norovirus among individuals. No significant correlation was found between IgG titres and blockade titres in the acute phase (R = 0.264, P = 0.213), convalescent phase (R = 0.184, P = 0.390) and the fold of increase (R = 0.196, P = 0.358).

Discussion

Noroviruses are recognised as the leading cause of acute viral gastroenteritis worldwide in all age groups, due to their low infectious dose, environmental stability and diverse transmission modes [27]. Norovirus-associated outbreaks or epidemics often occur in closed and semi-closed settings, such as large battleships, cruise ships, schools, hospitals and nursing homes [28]. Studies showed GII.6 noroviruses have widely circulated in many countries, such as in Korea, the USA, Peruvian, Australia and China [9, 29–31]. In Okayama, Japan, GII.6 norovirus-related infections accounted for 40.4% of all norovirus infection in non-hospitalised children with AGE, from 2008 to 2009 [32]. The virus was listed as the second most common genotype causing...
**Table 1.** Basic demographics, symptoms, stool tests and HBGA phenotypes of symptomatic and asymptomatic cases

| Group                        | Subject | Age  | Care unit | Vomiting | Diarrhoea | Norovirus detection | HBGA Phenotypes\(^a\) | Blood type\(^b\) | Paired sera collection |
|------------------------------|---------|------|-----------|----------|-----------|---------------------|------------------------|----------------------|-----------------------|
| **Symptomatic** *(n=27)*    | JS01    | 60   | 4         | 4        | 4         | −                   | B\(^d\), Le\(^h\), Le\(^r\) | B                    | −                     |
|                             | JS02    | 43   | 4         | 1        | 0         | −                   | H\(^e\), Le\(^h\), Le\(^r\) | O                    | −                     |
|                             | JS03    | 27   | 4         | 1        | 0         | +, GII.6            | A\(^h\), B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | AB                  | +                     |
|                             | JS04    | 46   | 4         | 1        | 0         | +, GII.6            | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | +                     |
|                             | JS05    | 32   | 4         | 1        | 0         | +, GII.6            | H\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | O                    | +                     |
|                             | JS06    | 45   | 4         | 1        | 0         | +, GII.6            | H\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | O                    | +                     |
|                             | JS07    | 46   | 4         | 1        | 0         | +, GII.6            | B\(^h\), Le\(^h\), Le\(^a\) | B                    | +                     |
|                             | JS08    | 36   | 4         | 2        | 0         | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | A                    | +                     |
|                             | JS09    | 53   | 4         | 0        | 4         | −                   | NP\(^e\)                  | −                    | −                     |
|                             | JS10    | 57   | 4         | 1        | 1         | −                   | H\(^h\), Le\(^h\), Le\(^a\) | O                    | −                     |
|                             | JS11    | 46   | 4         | 0        | 4         | −                   | Le\(^h\), Le\(^a\), Le\(^r\) | O                    | −                     |
|                             | JS12    | 32   | 3         | 2        | 1         | +, GII.6            | NP                   | NP                   | +                     |
|                             | JS13    | 37   | 3         | 1        | 0         | NP                  | NP                   | +                    | +                     |
|                             | JS14    | 52   | 3         | 1        | 0         | NP                  | NP                   | +                    | +                     |
|                             | JS15    | 37   | 3         | 1        | 1         | +, GII.6            | A\(^h\), B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | AB                  | +                     |
|                             | JS16    | 29   | 3         | 1        | 3         | +, GII.6            | NP                  | +                    | +                     |
|                             | JS17    | 65   | 3         | 0        | 2         | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\) | A                    | +                     |
|                             | JS18    | 38   | 3         | 2        | 0         | +, GII.6            | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | +                     |
|                             | JS19    | 53   | 3         | 1        | 0         | NP                  | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | +                     |
|                             | JS20    | 30   | 3         | 2        | 0         | +, GII.6            | NP                  | +                    | +                     |
|                             | JS21    | 53   | 3         | 1        | 2         | +, GII.6            | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | +                     |
|                             | JS22    | 62   | 3         | 1        | 0         | NP                  | NP                   | +                    | +                     |
|                             | JS23    | 62   | 3         | 0        | 3         | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | A                    | +                     |
|                             | JS24    | 35   | 3         | 1        | 0         | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | A                    | +                     |
|                             | JS25    | 62   | 3         | 0        | 5         | +, GII.6            | Le\(^h\), Le\(^a\), Le\(^r\) | O                    | +                     |
|                             | JS26    | 52   | 3         | 2        | 0         | +, GII.6            | H\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | O                    | +                     |
|                             | JS27    | 29   | 3         | 0        | 1         | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | A                    | +                     |
| **Asymptomatic infection** *(n=5)* | JS28    | 62   | 4         | 4        | +, GII.6 | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | −                    | −                     |
|                             | JS29    |      |          |          |          | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | A                    | −                    |
|                             | JS30    |      |          |          |          | +, GII.6            | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | +                    |
|                             | JS31    |      |          |          |          | +, GII.6            | A\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | A                    | +                    |
|                             | JS32    |      |          |          |          | +, GII.6            | B\(^h\), Le\(^h\), Le\(^a\), Le\(^r\) | B                    | −                    |

\(^a\)The subjects with HBGA phenotype indicating collection of saliva.

\(^b\)All individuals were detected as secretor with HBGA phenotyping.

\(^c\)The first case.

\(^d\)Le = Lewis.

\(^e\)NP, not perform without collecting saliva samples.

\(^f\)Doctor.
Fig. 1. The epidemic curve of the studied acute gastroenteritis outbreak by date of onset in a hospital of Jinshan in November 2018. Column chart indicating the numbers of acute gastroenteritis cases (Y-axis) in the two care units. X-axis shows dates.

Fig. 2. Phylogenetic tree analyses based on nucleotide sequences encoding capsid NS terminus (387 bp fragment) (a) and P domain (b) (978 bp fragment, corresponding to the nucleotide 661–1638 of the VP1 encoding gene) of GII.6 noroviruses. The sequences isolated were marked with a triangle and the tree made with reference strains using the neighbour-joining method. The bootstrap values generated from 1000 replicates are shown at each node. GII.6 strains were classified into three distinct clusters a–c.
outbreaks from 2014 to 2015 among young children in the USA [10]. As well as various other countries worldwide, molecular epidemiological studies in China also showed GII.6 noroviruses as commonly detected pathogens [33, 34]. In this study, we reported an outbreak of gastroenteritis in a hospital in Jinshan, Shanghai, China, in November 2018. With the use of field epidemiology and serologic investigations, we showed a GII.6/b norovirus as the causative agent of the outbreak.

Numerous studies support an association between norovirus infection and the human HBGA phenotypes, which may be an essential factor affecting the prevalence of GII norovirus [35–37]. GII.6 noroviruses consist of three clusters with some amino acid residues variations that can be detected after 40 years [14]. To further understand their prevalence in relation to HBGA binding profile, we analysed HBGA binding interfaces and the surrounding regions of different GII.6 clusters. Although these proteins were highly conserved, three amino acid residues mutations occurred among the clusters, which might lead to changes in HBGA binding patterns and affinities (Fig. 3). We noted that mutations occurred even in the same cluster. In a similar study involving two strains of cluster a, the A, B or O secretors bound the proteins, although one showed a weak

| variants                      | cluster | 343 | 345 | 346 | 347 | 349 | 350 | 391 | 406 | 409 | 451 | 452 | 453 | 454 | 455 |
|-------------------------------|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| DQ093604 Hu/Norovirus/GII.6/Sambu44/14/2000/JP | a       | F   | A   | T   | R   | A   | H   | E   | D   | G   | N   | A   | G   | G   | G   |
| AB073373 Hu/Norovirus/GII.6/Uneo79/4/2000/JP |         | F   | A   | T   | R   | A   | H   | E   | D   | G   | N   | A   | G   | G   | Y   |
| AF414407 Norwalk-like virus NLV/Florida/269/1993/US |       | F   | A   | T   | R   | A   | H   | E   | D   | G   | N   | A   | G   | G   | Y   |
| KY424342 Norovirus Hu/GII.6/BethesdaD74/2012/US |       | F   | _   | T   | R   | A   | H   | E   | D   | G   | D   | A   | G   | G   | Y   |
| LN654658 Norovirus Hu/GII.6/2014/Groningen |       | F   | _   | T   | R   | A   | H   | E   | D   | G   | D   | A   | G   | G   | Y   |
| Outbreak strain Norovirus Hu/GII.6/Jinshan 06/2018 |   | F   | _   | T   | R   | A   | H   | E   | D   | G   | D   | A   | G   | G   | Y   |
| KY424345 Norovirus Hu/GII.6/Heiyoug01/11/2012/JS |   | F   | _   | T   | R   | A   | H   | E   | D   | G   | D   | A   | G   | G   | Y   |
| AB518409 Norovirus Hu/GII.6/Enime12/02/2012/JP | c       | L   | T   | R   | A   | H   | E   | D   | Q   | D   | A   | G   | G   | G   | Y   |
| GU696066 Norovirus Hu/GII.6/8966/Maizuru/2008/JP |         | F   | R   | A   | H   | E   | D   | Q   | D   | A   | G   | G   | G   | G   | Y   |
| HM633213 Norovirus Hu/GII.6/8013/Shizuoka/2008/JP |         | F   | _   | T   | R   | A   | H   | E   | D   | Q   | D   | A   | G   | G   | Y   |

Fig. 3. Comparisons of P domain sequences that built the HBGA binding interfaces of GII.6 noroviruses and the neighbour regions. The representative sequences of GII.6 noroviruses are selected from different major phylogenetic clusters. The outbreak strain is shown with bold fonts. The sequences are aligned using MegAlign program (DNAstar 7.1). Amino acids in green are associated with HBGA binding, while those in light blue are related to the binding specificity based on previous studies [24, 25].

https://doi.org/10.1017/S0950268820002538 Published online by Cambridge University Press
bound to non-secretor salivas [26]. Our analysis showed a D (AB078337) to N (DQ093064) mutation in residue 390 at the binding interface, which might have resulted in the observed HBGA binding variations. These differences among the GII.6 clusters highlight the importance of understanding the relationship between the genetic variations and the host susceptibility

Fig. 4. Recombinant P protein of the studied GII.6/Jinshan 06 strain binding to well-characterised saliva samples representing various blood types. The binding signals are shown in optical density (Y-axis), while the well-characterised saliva (V as abbreviation for volunteers) [22] samples are shown in X-axis. A, B, O and N stands for blood type A, B, O and non-secretor, respectively.

Fig. 5. (a) and (b): GII.6-specific IgG titres (a) and blockade titres (b) against NoV GII.6 P domain binding to HBGA of the paired human sera collected from the outbreak. Blue (acute phase sera) and red (convalescent sera) columns show the IgG titres (a) or blockade titres (b), while different sera in indicating codes are shown in X-axis. The seroconversion between acute- and convalescent-phase sera were determined and shown. Green columns show the increased folds in GII.6 specific IgG titres or blocking titres by comparing their corresponding titres in the acute and convalescent sera.
for specific norovirus strains. We noted that the previous studies on associations between HBGA binding profiles and GII.6 norovirus infection were focused on clusters a and c. The pathogen causing the outbreak of our study was a GII.6 cluster b norovirus. Our data showed that all symptomatic cases and asymptomatic infected individuals were A, B or O secretors, which was further supported by our saliva-based HBGA-P protein assays. The saliva binding results of our study showed a difference from the results indicated that GII.6 cluster c VLPs (AB818400) with the highest binding signals to type A and lowest signals to type O saliva samples. These variations may be due to the observed minor mutations in the HBGA binding interfaces.

Previous studies also showed that GII.6 norovirus recognises HBGAs of A, B and O secretors with some minor variations [26, 38], suggesting that GII.6 noroviruses have a broad spectrum of target populations. Such studies also shed light on the host susceptibility, host range and epidemiology of GII.6 norovirus. Secretors represent 80–90% of the Chinese population [39] and this could be a crucial factor contributing to the high prevalence of GII.6 in the country. Thus, further surveillance of norovirus GII.6 variants is needed to get in-depth knowledge.

Genotype-specific blocking antibodies are correlated with protection against norovirus infection and the magnitude of such blocking titres are related to protection from natural infection [40, 41]. In this study, 83.3% of the infected cases showed relatively high IgG titres between 1000 and 8000 at the acute phase and their sera did not reveal blockade antibody titres against GII.6 variant (Fig. 5). Only four infected individuals showed low blockade antibody titres between 25 and 50 (Fig. 3b), suggesting a low specific blockade antibody titre was correlated with low blockade antibody titres between 25 and 50 (Fig. 3b), suggesting a low specific blockade antibody titre was correlated with infection at the beginning of the outbreak. Paired sera collected from norovirus outbreak gave valuable information for defining the correlation between protection and the magnitudes of pre-existing antibodies, as well as specific homologous immune response. It may also provide important data on cross immunity among different immunotypes, as newly recommended by Parra et al. [14]. To elucidate antigenic relatedness among different norovirus immunotypes, characterisation on cross immunity in both GI and GII genotypes are ongoing in our laboratory. We found that half of the symptomatic patients showed 4–32-folds blocking titre increase against GII.6 variant in the outbreak and these paired sera could serve as precious materials to define cross reaction and cross blockade between GII.6 and other genotypes in the future.

Studies showed that symptomatic individuals, compared to asymptomatic, have greater immune system activation and suggested that symptoms may be immune-mediated in norovirus infection [42]. In the present study, we found that two asymptomatic cases did not seroconvert, which supported their observation. Studies have shown that employees played an important role in the transmission during some norovirus outbreaks [43, 44]. A study showed that the infection rate of asymptomatic employee was 17.0% from 49 norovirus outbreaks in Shanghai [45]. In our study, the norovirus positive rate of convenience samples from asymptomatic staffs were 33.3%, which was consistent with the previous findings [46].

This study had some limitations. One was the relatively small size of infected individuals. A sampling of convenience may result in a selection bias that might further affect the accuracy of the study outcomes. Secondly, no saliva samples were collected from uninfected controls; as a result, the risk of secretor and non-secretor to GII.6 infection could not be evaluated.

In conclusion, the study represents an investigation on a gastroenteritis outbreak caused by GII.6/b norovirus, focusing on epidemiology, host susceptibility, host HBGA phenotypes and HBGA binding profiles of causative norovirus. A low specific blockade antibody in the population may play an important role at the beginning of the outbreak. A wide HBGA-binding spectrum is useful in understanding the epidemiology, host susceptibility and host range of GII.6 norovirus, supporting a need for continuous health attention and surveillance in different settings.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0950268820002538

Data availability statement. The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.

Acknowledgements. The study was supported by the National Natural Science Foundation of China (grant numbers 31771007, 81773975); Natural Science Foundation of Guangdong Province, China (grant numbers 2019A151010951); and Science and Technology Commission of Shanghai Municipality (grant numbers 201940428).

Conflicts of interest. None.

Ethics approval and consent to participate. Sample collection was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University and informed consent was obtained from each involved individual.

References

1. Lopman BA et al. (2016) The vast and varied global burden of norovirus: prospects for prevention and control. PloS Medicine 13, e1001999.
2. Zhou HL et al. (2017) Burden of acute gastroenteritis caused by norovirus in China: a systematic review. The Journal of Infection 75, 216–224.
3. Bányai K et al. (2018) Viral gastroenteritis. The Lancet 392, 175–186.
4. Chhabra P et al. (2019) Updated classification of norovirus genogroups and genotypes. The Journal of General Virology 100, 1393–1406.
5. Nordgren J and Svensson I (2019) Genetic susceptibility to human norovirus infection: an update. Viruses 11, 1393–1406.
6. Tan M and Jiang X (2011) Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends in Microbiology 19, 382–388.
7. Tan M and Jiang X (2010) Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathogens 6, e1000983.
8. Parra GI and Green KY (2014) Sequential gastroenteritis episodes caused by 2 norovirus genotypes. Emerging Infectious Diseases 20, 1016–1018.
9. Bruggink LD, Moselen JM and Marshall JA (2016) The comparative molecular epidemiology of GILP7_GIL6 and GILP7_GIL7 norovirus outbreaks in Victoria, Australia, 2012–2014. Intervirology 59, 60–65.
10. Cannon JL et al. (2017) Genetic and epidemiologic trends of norovirus outbreaks in the United States from 2013 to 2016 demonstrated emergence of novel GIL4 recombinant viruses. Journal of Clinical Microbiology 55, 2208–2221.
11. Currier RL et al. (2015) Innate susceptibility to norovirus infections influenced by FUT2 genotype in a United States pediatric population. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 60, 1631–1638.
12. Sharma S et al. (2019) Secretor status is associated with susceptibility to disease in a large GIL6 norovirus foodborne outbreak. Food and Environmental Virology 12, 28–34.
13. Karangwa CK et al. (2017) Sequential gastroenteritis outbreaks in a single year caused by norovirus genotypes GIL2 and GIL6 in an institutional setting. Open Forum Infectious Diseases 4, 1–8. ofx236.
14. Parra GI et al. (2017) Static and evolving norovirus genotypes: implications for epidemiology and immunity. PLoS Pathogens 13, e1006136.
15. Zheng QM et al. (2015) Epidemiological investigation of a norovirus GIL4 Sydney outbreak in a China elder care facility. Japanese Journal of Infectious Diseases 68, 70–74.
16. Wolf S et al. (2007) Sensitive multiplex real-time reverse transcription-PCR assay for the detection of human and animal noroviruses in clinical and environmental samples. Applied and Environmental Microbiology 73, 5464–5470.

17. Kojima S et al. (2002) Genogroup-specific PCR primers for detection of Norwalk-like viruses. Journal of Virological Methods 100, 107–114.

18. Kroneman A et al. (2011) An automated genotyping tool for enteroviruses and noroviruses. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 51, 121–125.

19. Tan M and Jiang X (2005) The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. Journal of Virology 79, 14017–14030.

20. Dai YC et al. (2017) Characterization of antigenic relatedness between GII.4 and GII.17 noroviruses by use of serum samples from norovirus-infected patients. Journal of Clinical Microbiology 55, 3366–3373.

21. Zhang XF et al. (2016) P[8] and P[4] rotavirus infection associated with secretor phenotypes among children in South China. Scientific Reports 6, 34591.

22. Tang Y et al. (2013) Study on the relationship between norovirus outbreak and HBGAs receptor. Advances in Modern Biomedicine 13, 683–687+704.

23. Reeck A et al. (2010) Serological correlate of protection against norovirus-induced gastroenteritis. The Journal of Infectious Diseases 202, 1212–1218.

24. Tan M et al. (2008) Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology 379, 324–334.

25. Tan M et al. (2009) Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PloS One 4, e5058.

26. Shirato H et al. (2008) Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. Journal of Virology 82, 10756–10767.

27. Karst SM, Zhu S and Goodfellow IG (2015) The molecular pathology of noroviruses. The Journal of Pathology 235, 206–216.

28. Lian Y et al. (2019) Epidemiology of norovirus outbreaks reported to the public health emergency event surveillance system, China, 2014–2017. Viruses 11, 1–12.

29. Park SH et al. (2011) Viral agents associated with acute gastroenteritis in Seoul, Korea. Clinical Laboratory 57, 59–65.

30. Vega E et al. (2014) Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. Journal of Clinical Microbiology 52, 147–155.

31. Saito M et al. (2014) Multiple norovirus infections in a birth cohort in a Peruvian Peruvian community. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America 58, 483–491.

32. Chan-It W et al. (2012) Emergence of a new norovirus GIIL6 variant in Japan, 2008–2009. Journal of Medical Virology 84, 1089–1096.

33. Guo Z et al. (2014) A food-borne outbreak of gastroenteritis caused by norovirus GI in a university located in Xiamen City, China. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases 28, 101–106.

34. Luo JF et al. (2015) Acute gastroenteritis outbreak caused by a GIIL6 norovirus. World Journal of Gastroenterology 21, 5295–5302.

35. Zhang XF et al. (2015) An outbreak caused by GIIL7 norovirus with a wide spectrum of HBGA-associated susceptibility. Scientific Reports 5, 17687.

36. Dai YC et al. (2015) Antigenic relatedness of norovirus GIIL4 variants determined by human challenge sera. PLOS One 10, e0124945.

37. Liu W et al. (2015) A unique human norovirus lineage with a distinct HBGA binding interface. PLoS Pathogens 11, e1005025.

38. Zheng L et al. (2017) Comprehensive characterization of a major capsid protein derived from a documented GIIL6 norovirus strain. Archives of Virology 162, 3863–3888.

39. Tan M and Jiang X (2014) Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert Reviews in Molecular Medicine 16, e5.

40. Malm M et al. (2014) High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children. The Journal of Infectious Diseases 210, 1755–1762.

41. Atmar RL et al. (2020) Comparison of microneutralization and histo-blood group antigen-blocking assays for functional norovirus antibody detection. The Journal of Infectious Diseases 221, 1047–1048.

42. Newman KL et al. (2016) Norovirus in symptomatic and asymptomatic individuals: cytokines and viral shedding. Clinical and Experimental Immunology 184, 347–357.

43. Chen MY et al. (2016) An outbreak of norovirus gastroenteritis associated with asymptomatic food handlers in Kinmen, Taiwan. BMC Public Health 16, 372.

44. Xue C et al. (2014) An outbreak of acute norovirus gastroenteritis in a boarding school in Shanghai: a retrospective cohort study. BMC Public Health 14, 1092.

45. Wu QS et al. (2019) Norovirus shedding among symptomatic and asymptomatic employees in outbreak settings in Shanghai, China. BMC Infectious Diseases 19, 592.

46. Bok K and Green KY (2012) Norovirus gastroenteritis in immunocompromised patients. The New England Journal of Medicine 367, 2126–2132.